Ney Carter Borges: Contemporary Trends and Outcomes of Percutaneous Coronary Intervention for Stent Thrombosis
Ney Carter Borges, Member Cardiologist of Global Physician Association at Cleveland Clinic Florida, shared a post on LinkedIn:
”Contemporary Trends and Outcomes of Percutaneous Coronary Intervention for Stent Thrombosis
Stent thrombosis (ST) remains one of the most serious complications following percutaneous coronary intervention (PCI), frequently presenting as acute myocardial infarction (AMI). A contemporary analysis from the National Cardiovascular Data Registry (NCDR) CathPCI registry evaluated trends and outcomes of PCI performed for ST between April 2018 and June 2023. The study included 2,023,032 patients undergoing PCI for AMI, of whom 57,268 cases (2.8%) were attributed to stent thrombosis.
Regarding timing, very late ST (>365 days) represented the largest proportion of cases (49.5%), followed by early ST (≤30 days) at 31.8%, late ST (31–365 days) at 15.4%, and unknown timing in 3.4% of cases. Importantly, the incidence of PCI for ST remained stable over time, despite advances in contemporary PCI techniques, including newer-generation drug-eluting stents, potent P2Y12 inhibitors, and intracoronary imaging.
Clinically, patients with ST tended to be younger, more frequently male, and more likely to present with STEMI, cardiogenic shock, cardiac arrest, and ventricular arrhythmias, reflecting a high-risk population. Compared with PCI for non-ST lesions, PCI performed for ST was associated with significantly worse in-hospital outcomes, including higher rates of major adverse cardiac events (adjusted OR 1.24), all-cause mortality (OR 1.17), recurrent myocardial infarction (OR 1.80), and major bleeding (OR 1.18).
These findings highlight that, despite technological and pharmacologic advances, stent thrombosis remains a rare but high-risk complication of PCI, emphasizing the need for improved preventive strategies, optimized antithrombotic therapy, and procedural techniques to reduce its clinical impact.”

Other posts featuring Ney Carter Borges on Hemostasis Today.
-
Aug 14, 2026, 11:40Liz Devlin: When HHT Affects More Than What We Can See
-
Aug 14, 2026, 11:29Archil Jaliashvili: Can Italy Reduce Its Dependence on Imported Plasma
-
Aug 14, 2026, 11:21Osama Alabdi: Never Ignore a Weak Reaction in the Blood Bank
-
Aug 14, 2026, 11:14Yohan Santin: How Lysosomal Dysfunction Drives Cardiac Aging
-
Aug 14, 2026, 11:06Nicolas Schommer: When Neutrophils Turn Metabolic Stress Into Organ Injury
-
Aug 14, 2026, 10:49Pablo Corral: Can One Infusion Lower LDL for Years
-
Aug 14, 2026, 08:17Maha Othman: Celebrating Research and Collaboration at the Sinclair Cancer Research Institute 2026 Annual Retreat
-
Aug 14, 2026, 06:26Delivering Gene Therapy in Hemophilia – ISTH
-
Aug 13, 2026, 18:39Lukas Röthlisberger: Real-World Evidence on Effectiveness and Safety of Rivaroxaban in Children